Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification

Histopathology

Volumn 69, Issue 5, 2016, Pages 717-726

  Compérat, Eva ^a,b   Varinot, Justine ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

bladder cancer; immunohistochemistry; molecular classification; WHO classification

Indexed keywords

CANCER GRADING; CANCER STAGING; CLASSIFICATION; FAMILIAL CANCER; GENE MUTATION; HUMAN; IMMUNOCHEMISTRY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; REVIEW; TISSUE SECTION; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; WORLD HEALTH ORGANIZATION; BLADDER TUMOR; IMMUNOHISTOCHEMISTRY; MALE;

CARCINOMA, TRANSITIONAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; URINARY BLADDER NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 84987915576     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.13025     Document Type: Review

References (39)

1. Moch H, Humphrey PA, Ulbright TM, Reuter V. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer, 2016.
2. Keck B, Wach S, Stoehr R et al. Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer 2013; 13; 71–78.
3. Höglund M. On the origin of syn- and metachronous urothelial carcinomas. Eur. Urol. 2007; 51; 1185–1193; discussion 1193.
4. Cox R, Epstein JI. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am. J. Surg. Pathol. 2011; 35; 1337–1342.
5. Dayyani F, Czerniak BA, Sircar K et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J. Urol. 2013; 189; 1656–1661.
6. Oliva E, Amin MB, Jimenez R, Young RH. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumours of Mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems. Am. J. Surg. Pathol. 2002; 26; 190–197.
7. Lopez-Beltran A, Amin MB, Oliveira PS et al. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. Am. J. Surg. Pathol. 2010; 34; 371–376.
8. Kurosaka S, Irie A, Mizoguchi H, Okuno N, Iwabuchi K, Baba S. Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy. Int. J. Clin. Oncol. 2005; 10; 362–365.
9. Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. J. Urol. 1984; 131; 1–8.
10. Gopalan A, Sharp DS, Fine SW et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am. J. Surg. Pathol. 2009; 33; 659–668.
11. Colarossi C, Pino P, Giuffrida D et al. Large cell neuroendocrine carcinoma (LCNEC) of the urinary bladder: a case report. Diagn. Pathol. 2013; 4; 8–19.
12. Patel P, Gotto G, Kavanagh A, Al Bashir S, Bismar TA, Trpkov K. Urinary bladder melanosis associated with urothelial dysplasia and invasive urothelial carcinoma: a report of two cases. Anal. Quant. Cytopathol. Histopathol. 2013; 35; 294–300.
13. Williamson SR, Bunde PJ, Montironi R et al. Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features. Am. J. Surg. Pathol. 2013; 37; 1619–1626.
14. Lopez-Beltran A, Cheng L. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. Pathology 2003; 35; 484–491.
15. Tosoni I, Wagner U, Sauter G et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int. 2000; 85; 48–53.
16. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumours. J. Urol. 1999; 162; 74–76.
17. Compérat E, Egevad L, Lopez-Beltran A et al. An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology 2013; 63; 756–766.
18. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990; 66; 543–548.
19. Dixon JS, Gosling JA. Histology and fine structure of the muscularis mucosae of the human urinary bladder. J. Anat. 1983; 136(Pt 2); 265–271.
20. Bertz S, Denzinger S, Otto W et al. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer – evaluation of a large hospital-based single-centre series. Histopathology 2011; 59; 722–732.
21. Rouprêt M, Seisen T, Compérat E et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J. Urol. 2013; 189; 2069–2076.
22. Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999; 86; 1035–1043.
23. van der Aa MNM, van Leenders GJLH, Steyerberg EW et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum. Pathol. 2005; 36; 981–986.
24. Chang W-C, Chang Y-H, Pan C-C. Prognostic significance in substaging of T1 urinary bladder urothelial carcinoma on transurethral resection. Am. J. Surg. Pathol. 2012; 36; 454–461.
25. Datasets—International Collaboration on Cancer Reporting. Available at: http://www.iccr-cancer.org/datasets
26. Paner GP, Annaiah C, Gulmann C et al. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum. Pathol. 2014; 45; 1473–1482.
27. Mohanty SK, Smith SC, Chang E et al. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas. Am. J. Clin. Pathol. 2014; 142; 173–183.
28. Amin MB, Smith SC, Reuter VE et al. Update for the practicing pathologist: the International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Mod. Pathol. 2015; 28; 612–630.
29. Compérat E, Camparo P, Haus R et al. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch. 2007; 450; 419–424.
30. Owen HC, Giedl J, Wild PJ et al. Low frequency of epigenetic events in urothelial tumours in young patients. J. Urol. 2010; 184; 459–463.
31. Figueroa JD, Middlebrooks CD, Banday AR et al. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum. Mol. Genet. 2016; 25; 1203–1214.
32. Majewski T, Lee S, Jeong J et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab. Invest. 2008; 88; 694–721.
33. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 2015; 15; 25–41.
34. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507; 315–322.
35. Sjödahl G, Lauss M, Lövgren K et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 2012; 18; 3377–3386.
36. Patschan O, Sjödahl G, Chebil G et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur. Urol. 2015; 68; 824–832.
37. Choi W, Porten S, Kim S et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014; 25; 152–165.
38. Witjes JA, Compérat E, Cowan NC et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur. Urol. 2014; 65; 778–792.
39. McConkey DJ, Choi W, Shen Y et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a Phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur. Urol. 2016; 69; 855–862.